Citigroup
ANTX icon

Citigroup’s AN2 Therapeutics ANTX Stock Holding History

Citigroup’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.4K Sell
12,267
-6,821
-36% -$29.3K ﹤0.01% 4916
2026
Q1 		$65.3K Buy
+19,088
New +$39.4K ﹤0.01% 4427
2024
Q3 		– Sell
-37,887
Closed -$81.5K – 5669
2024
Q2 		$81.5K Sell
37,887
-32,920
-46% -$78.4K ﹤0.01% 4319
2024
Q1 		$230K Sell
70,807
-89,679
-56% -$976K ﹤0.01% 3945
2023
Q4 		$3.29M Buy
160,486
+1,381
+0.9% +$23.1K ﹤0.01% 1875
2023
Q3 		$2.56M Buy
159,105
+24,632
+18% +$279K ﹤0.01% 1830
2023
Q2 		$1.14M Hold
134,473
– – ﹤0.01% 2744
2023
Q1 		$1.33M Sell
134,473
-75
-0.1% -$834 ﹤0.01% 2342
2022
Q4 		$1.28M Buy
134,548
+3
+0% +$40 ﹤0.01% 2394
2022
Q3 		$2.34M Buy
134,545
+46,770
+53% +$545K ﹤0.01% 2037
2022
Q2 		$680K Buy
+87,775
New +$1.16M ﹤0.01% 2991

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Citigroup's ANTX Position: Q2 2026 in Review

Citigroup reduced its AN2 Therapeutics (ANTX) stake by 36% in Q2 2026, selling an estimated $29.3K and leaving 12,267 shares worth $59.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4916.

Citigroup first reported a position in ANTX in Q2 2022 and has held it in 11 quarters since. The position peaked at $3.29M in Q4 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Citigroup held 12,267 shares of AN2 Therapeutics worth $59.4K as of Q2 2026.
  • Citigroup sold 6,821 AN2 Therapeutics shares in Q2 2026, an estimated $29.3K.
  • AN2 Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4916 holding.
  • Citigroup first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Citigroup's AN2 Therapeutics position peaked at $3.29M in Q4 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.